These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34536265)

  • 1. Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES.
    Yeoh SE; Dewan P; Serenelli M; Ferreira JP; Pitt B; Swedberg K; van Veldhuisen DJ; Zannad F; Jhund PS; McMurray JJV
    Eur J Heart Fail; 2022 Mar; 24(3):529-538. PubMed ID: 34536265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF.
    Dewan P; Docherty KF; Bengtsson O; de Boer RA; Desai AS; Drozdz J; Hawkins NM; Inzucchi SE; Kitakaze M; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez FA; Merkely B; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Sjöstrand M; Solomon SD; Verma S; Jhund PS; McMurray JJV
    Eur J Heart Fail; 2021 Apr; 23(4):632-643. PubMed ID: 33368858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.
    Jhund PS; Talebi A; Henderson AD; Claggett BL; Vaduganathan M; Desai AS; Lam CSP; Pitt B; Senni M; Shah SJ; Voors AA; Zannad F; Solomon SD; McMurray JJV
    Lancet; 2024 Sep; 404(10458):1119-1131. PubMed ID: 39232490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
    Serenelli M; Jackson A; Dewan P; Jhund PS; Petrie MC; Rossignol P; Campo G; Pitt B; Zannad F; Ferreira JP; McMurray JJV
    JACC Heart Fail; 2020 Mar; 8(3):188-198. PubMed ID: 31926854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT.
    Ferreira JP; Rossello X; Eschalier R; McMurray JJV; Pocock S; Girerd N; Rossignol P; Pitt B; Zannad F
    JACC Heart Fail; 2019 Dec; 7(12):1012-1021. PubMed ID: 31779922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
    Ehteshami-Afshar S; Mooney L; Dewan P; Desai AS; Lang NN; Lefkowitz MP; Petrie MC; Rizkala AR; Rouleau JL; Solomon SD; Swedberg K; Shi VC; Zile MR; Packer M; McMurray JJV; Jhund PS; Hawkins NM
    J Am Heart Assoc; 2021 Feb; 10(4):e019238. PubMed ID: 33522249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: Data from Swedish Heart Failure Registry.
    Guidetti F; Lund LH; Benson L; Hage C; Musella F; Stolfo D; Mol PGM; Flammer AJ; Ruschitzka F; Dahlstrom U; Rosano GMC; Braun OÖ; Savarese G
    Eur J Heart Fail; 2023 Dec; 25(12):2164-2173. PubMed ID: 37795642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
    Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
    Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HFrEF) discharge medication prescribing: Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions?
    Richardson A; Tolley E; Hartmann J; Reedus J; Bowlin B; Finch C; Sands CW; Self T
    Respir Med; 2016 Oct; 119():135-140. PubMed ID: 27692135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.
    Shen L; Kristensen SL; Bengtsson O; Böhm M; de Boer RA; Docherty KF; Inzucchi SE; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez MFA; O'Meara E; Nicolau JC; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV
    JACC Heart Fail; 2021 Apr; 9(4):254-264. PubMed ID: 33549554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of beta-blocker use on the long-term outcomes of heart failure patients with chronic obstructive pulmonary disease.
    Kubota Y; Tay WT; Teng TK; Asai K; Noda T; Kusano K; Suzuki A; Hagiwara N; Hisatake S; Ikeda T; Yasuoka R; Kurita T; Shimizu W;
    ESC Heart Fail; 2021 Oct; 8(5):3791-3799. PubMed ID: 34189870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials.
    Rossello X; Ferreira JP; Pocock SJ; McMurray JJV; Solomon SD; Lam CSP; Girerd N; Pitt B; Rossignol P; Zannad F
    Eur J Heart Fail; 2020 May; 22(5):834-844. PubMed ID: 32077220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction.
    Jaiswal A; Chichra A; Nguyen VQ; Gadiraju TV; Le Jemtel TH
    Curr Heart Fail Rep; 2016 Feb; 13(1):30-6. PubMed ID: 26780914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction.
    Matsumoto S; Kondo T; Jhund PS; Campbell RT; Swedberg K; van Veldhuisen DJ; Pocock SJ; Pitt B; Zannad F; McMurray JJV
    J Am Coll Cardiol; 2023 Sep; 82(11):1080-1091. PubMed ID: 37642608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry.
    Savarese G; Carrero JJ; Pitt B; Anker SD; Rosano GMC; Dahlström U; Lund LH
    Eur J Heart Fail; 2018 Sep; 20(9):1326-1334. PubMed ID: 29578280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
    Brunner-La Rocca HP; Linssen GC; Smeele FJ; van Drimmelen AA; Schaafsma HJ; Westendorp PH; Rademaker PC; van de Kamp HJ; Hoes AW; Brugts JJ;
    JACC Heart Fail; 2019 Jan; 7(1):13-21. PubMed ID: 30606482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should MRAs be at the front row in heart failure? A plea for the early use of mineralocorticoid receptor antagonists in medical therapy for heart failure based on clinical experience.
    Heggermont WA; Goethals M; Dierckx R; Verstreken S; Bartunek J; Vanderheyden M
    Heart Fail Rev; 2016 Nov; 21(6):699-701. PubMed ID: 27620301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor antagonists for heart failure: a real-life observational study.
    Bruno N; Sinagra G; Paolillo S; Bonomi A; Corrà U; Piepoli M; Veglia F; Salvioni E; Lagioia R; Metra M; Limongelli G; Cattadori G; Scardovi AB; Carubelli V; Scrutino D; Badagliacca R; Guazzi M; Raimondo R; Gentile P; Magrì D; Correale M; Parati G; Re F; Cicoira M; Frigerio M; Bussotti M; Vignati C; Oliva F; Mezzani A; Vergaro G; Di Lenarda A; Passino C; Sciomer S; Pacileo G; Ricci R; Contini M; Apostolo A; Palermo P; Mapelli M; Carriere C; Clemenza F; Binno S; Belardinelli R; Lombardi C; Perrone Filardi P; Emdin M; Agostoni P
    ESC Heart Fail; 2018 Jun; 5(3):267-274. PubMed ID: 29397584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Banerjee M; Maisnam I; Pal R; Mukhopadhyay S
    Eur Heart J; 2023 Oct; 44(37):3686-3696. PubMed ID: 37605637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
    Verma S; Dhingra NK; Butler J; Anker SD; Ferreira JP; Filippatos G; Januzzi JL; Lam CSP; Sattar N; Peil B; Nordaby M; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    Lancet Diabetes Endocrinol; 2022 Jan; 10(1):35-45. PubMed ID: 34861154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.